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Abstract
Introduction: Gene amplification is an important mechanism for activating oncogenes in malignant tumors.
Although amplification of HER2, C-MYC, CCND1 and FGFR1 has been reported in breast cancers, their role in the
progression of in situ to invasive breast carcinoma is unclear. To investigate this question we compared the
amplification frequencies of these genes in pure ductal carcinoma in situ (DCIS), DCIS associated with invasive
carcinoma, and invasive carcinoma.
Methods: We performed fluorescence in situ hybridization of the selected genes on tissue microarrays composed
of 179 pure DCIS and 438 invasive carcinomas. Two hundred and sixteen of the latter had DCIS components, and
in those cases we compared gene amplification in the intraductal and invasive components of each carcinoma.
Results: The rate of amplification of FGFR1 was higher in invasive carcinomas than in the pure DCIS, but the
opposite was true for HER2 amplification. These findings applied consistently to high-grade tumors, but not to low/
intermediate-grade tumors. The amplification status of HER2, C-MYC, CCND1 and FGFR1 was generally similar in the
matched invasive and DCIS components of the same tumors. However, FGFR1 amplification was more common in
the invasive components than in the DCIS components. In survival analyses, FGFR1 amplification was found to be
an independent prognostic factor for poor disease-free survival for all patients with invasive carcinoma and for the
hormone receptor-positive subgroup.
Conclusion: Amplification of HER2, C-MYC and CCND1 seems to play a role in the early development of breast
cancer, but not in its progression. However, the increased frequency of FGFR1 amplification in invasive carcinomas
compared with pure DCIS and in the invasive components of individual tumors, and its association with decreased
disease-free survival, suggests a role for FGFR1 amplification in the progression of breast cancer including in situ-to-
invasive transition, as well as initiation.
Introduction
Development of breast cancer depends on the accumu-
lation of a variety of genetic alterations, including activa-
tion or amplification of oncogenes [1]. In breast cancer,
the most prominent and frequent amplicons have been
located at chromosomal positions 1q, 8p12, 8q24,
11q13, 12p13, 16p13, 7q12-21 and 20q13, and several
target oncogenes have been identified [2-5]. The best
characterized oncogene is HER2, located at 17q12-21,
which is amplified in 15 to 20% of breast cancers [6,7].
Other oncogenes that are frequently amplified in breast
cancer include C-MYC, FGFR1 and CCND1. C-MYC,
located at 8q24, encodes a transcription factor with a
basic region/helix-loop-helix/leucine zipper domain,
which is a key regulator of cell growth, proliferation,
metabolism, differentiation, and apoptosis [8]. The fre-
quency of C-MYC amplification in breast cancer varies,
with an average frequency of 16% [9]. Although C-MYC
amplification is associated with a risk of relapse and
death [9-12], its prognostic role is still unclear. FGFR1
at 8p12 encodes a tyrosine kinase receptor belonging to
the fibroblast growth factor and growth factor receptor
family, which is amplified in 9 to 15% of breast cancers
[13-16]. FGFR1 amplification is associated with a poor
prognosis in breast cancer [14,16,17]. CCND1, located at
11q13, is an estrogen-responsive gene with oncogenic
* Correspondence: sypmd@snu.ac.kr
1Department of Pathology, Seoul National University College of Medicine,
103 Daehakro, Jongno-gu, Seoul 110-799, Korea
Full list of author information is available at the end of the article
Jang et al. Breast Cancer Research 2012, 14:R115
http://breast-cancer-research.com/content/14/4/R115
© 2012 Jang et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
potential as it influences the G1/S phase transition [18].
CCND1is amplified in 13 to 20% of breast cancers
[2,16,19].
Ductal carcinoma in situ (DCIS) is an early pathologic
stage of breast cancer characterized by proliferation of
tumor cells within the ductal-lobular system but not
extending through the basement membrane. Like invasive
breast cancer, DCIS comprises a highly heterogeneous
group of diseases with diverse histologic features, molecu-
lar alterations and risks of progression to invasive cancer
[20-22]. There appear to be at least two broad groups of
DCIS lesions: low-grade DCIS characterized by 16q loss
and 1q gain, and high-grade DCIS displaying complex
genetic changes including gains at chromosome locations
8q and 17q [23-25]. Molecular studies have revealed that
in situ lesions preferentially cluster with invasive lesions of
the same grade in gene expression profiling, and that the
in situ and invasive components of the same tumor exhibit
similar patterns of genetic alterations, suggesting that
DCIS is a precursor for invasive cancer of similar grade
[23,25,26].
The natural history of DCIS is poorly understood,
although it is known that 14 to 53% of in situ lesions
evolve to invasive cancer over a period of 10 years or more
if left untreated [20]. The mechanisms by which DCIS
progress to invasive carcinomas are not well understood,
and robust biomarkers capable of stratifying the aggressive
forms of DCIS from the indolent forms are lacking. More-
over, the role of gene amplification in the progression of
DCIS to invasive breast cancer is uncertain. Some workers
found no difference in gene amplification frequencies
between DCIS and invasive carcinomas [27-29]. Others
have suggested that C-MYC amplification plays an impor-
tant role in the transition, because they found amplifica-
tion only in the invasive component [30,31]. However, this
finding was not confirmed in other studies [27-29].
Furthermore, there have been few studies comparing
amplification of FGFR1 in pure DCIS, DCIS associated
with invasive cancer, and invasive breast cancer, although
it has been found to be associated with breast cancer pro-
gression [14,16,17].
In this study, we compared the gene amplification fre-
quencies of HER2, C-MYC, CCND1 and FGFR1 in a rela-
tively large series of pure DCIS, DCIS associated with
invasive carcinoma, and invasive carcinomas, to investigate
the role of gene amplification in the progression of DCIS
to invasive carcinomas. We also analyzed the gene amplifi-
cation status of the in situ and invasive components in the
invasive carcinomas that were accompanied by DCIS.
Materials and methods
Tissue specimens
Six hundred and seventeen consecutively resected pri-
mary breast cancers including 438 invasive carcinomas
and 179 DCIS were collected in Seoul National Univer-
sity Bundang Hospital from 2003 to 2009. Of the 438
invasive breast cancers, 216 cases had enough DCIS com-
ponent for evaluation. The baseline characteristics of the
cases are summarized in Table 1. Clinicopathologic infor-
mation was obtained by reviewing medical records and H
& E-stained sections. The following histopathologic vari-
ables of the invasive carcinomas were determined: histo-
logic subtype, T stage, N stage, Bloom-Richardson
histologic grade, lymphovascular invasion, tumor border,
and presence or absence of a DCIS component. For
DCIS cases, we recorded the extent of tumor, nuclear
grade, presence of necrosis and architectural pattern. All
cases were independently reviewed by two breast pathol-
ogists (SYP and HEL). The study was approved by the
institutional review board of Seoul National University
Bundang Hospital (Protocol # B-0909/083-002), waiving
the requirement for informed consent for the study.


















Invasive ductal carcinoma 397 (90.6)
Invasive lobular carcinoma 14 (3.2)
Mucinous carcinoma 12 (2.7)
Metaplastic carcinoma 5 (1.1)
Tubular carcinoma 3 (0.7)
Others 7 (1.6)
Histologic grade
Grade I 88 (20.1)
Grade II 148 (33.8)
Grade III 188 (42.9)
Not determined 14 (3.2)




aFrom 216 ductal carcinoma in situ (DCIS) associated with invasive carcinoma.
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Tissue microarray construction
We used tissue microarrays (TMAs) to assess the gene
amplification status in the collected cases. To overcome
sampling errors caused by TMA evaluation, all slides
including slides immunohistochemically stained for stan-
dard biomarkers were reviewed and the most representa-
tive tumor section was selected for each case. If the tumor
showed regional differences in histology or biomarker
expression, different tumor areas were selected. Three tis-
sue columns of invasive carcinoma and pure DCIS
(2.0 mm in diameter for invasive carcinomas, 4.0 mm in
diameter for DCIS) were taken from different areas of the
tumors and arranged in new TMA blocks using a trephine
apparatus (Superbiochips Laboratories, Seoul, Korea). Lots
of DCIS associated with invasive carcinoma were not large
enough for multi-core construction, and one tissue col-
umn of DCIS associated with invasive carcinoma (4.0 mm
in diameter) was selected. However, because the analysis
of DCIS associated with invasive carcinoma in a single
TMA core may not be representative, we re-evaluated the
discrepant cases for gene amplification between DCIS and
invasive components of the same tumor using all tumor
sections with a DCIS component.
Fluorescence in situ hybridization assays
To characterize C-MYC and CCND1 amplification, we
performed fluorescence in situ hybridization (FISH) ana-
lyses on TMA samples with commercially available locus-
specific probes and chromosome enumeration probes
(CEPs): LSI C-MYC SpectrumOrange probe (8q24.12-
q24.13) and CEP 8 SpectrumGreen probe (8p11.1-q11.1);
and LSI CCND1 SpectrumOrange probe (11q13) and CEP
11 SpectrumGreen probe (11p11.11-q11)] (Abbott Mole-
cular, Downers Grove, IL, USA). HER2 FISH was per-
formed using the PathVysion assay (Abbott Molecular),
and FGFR1 amplification was analyzed with locus-specific
BAC, RP11-100B16 (chr8:38,358,839-38,522,417) and CEP
8 SpectrumGreen probes (8p11.1-q11.1) (Abbott Molecu-
lar). The BAC clone was obtained from Invitrogen (Carls-
bad, CA, USA) and purified with a large construction kit
(Qiagen, Valencia, CA, USA). DNA from the BAC clone
was labeled with SpectrumOrange using a nick translation
kit (Abbott Molecular), and the specificity of the BAC
probe was verified by metaphase FISH analyses to confirm
their proper chromosomal localization and rule out the
presence of any cross-hybridization.
FISH was performed as reported for analysis of HER2
amplification [32]. Briefly, 4 μm deparaffinized TMA sec-
tions were incubated in pretreatment solution (Abbott
Molecular) at 80°C for 30 minutes, then in protease solu-
tion (Abbott Molecular) for 20 minutes at 37°C. Probes
were diluted in tDen-Hyb-2 hybridization buffer (InSitus
Biotechnologies, Albuquerque, NM, USA). Co-denatura-
tion of the probes and DNA of the tissue sections was
achieved by incubating for 5 minutes (73°C for HER2, 80°C
for C-MYC and CCND1, 90°C for FGFR1) using HYBrite™
(Abbott Molecular) followed by 16-hour hybridization at
37°C. Post-hybridization washes were performed according
to the protocols supplied. Slides were mounted in 4’,6-dia-
midino-2-phenylindole/anti-fade and viewed with a fluor-
escence microscope. Gene signals per cell were evaluated
in 50 tumor nuclei for each TMA core. The average gene
copy number and gene:CEP ratio was calculated separately
for each core, and the tumor was considered amplified if
the average gene copy number was > 6.0 or if the gene:
CEP signal ratio was > 2.2 in at least a core. In addition to
the equivocal cases, 10% of all cases were scored indepen-
dently by two observers (MHJ and EJK).
Immunohistochemical analyses and scoring
Expression of standard biomarkers including estrogen
receptor (ER), progesterone receptor (PR), HER2, p53 and
Ki-67 was evaluated in full sections at the time of diagnosis
or in TMA sections for missing data during the study. Epi-
dermal growth factor receptor (EGFR) and cytokeratin 5/6
were evaluated using TMAs. Tissue sections 4 μm thick
were cut, dried, deparaffinized, and rehydrated following
standard procedures. All of the sections were subjected to
heat-induced antigen retrieval. Immunohistochemical
staining was carried out in a BenchMark XT autostainer
(Ventana Medical Systems, Tucson, AZ, USA) using an i-
View detection kit (Ventana Medical Systems) for ER
(1:100, clone SP1; Labvision, Fremont, CA, USA), PR (1:70,
PgR 636; Dako, Capinteria, CA, USA), HER2 (1:700, poly-
clonal; Dako), p53 (1:600, D07; Dako), Ki-67 (1:250, MIB-1;
Dako), cytokeratin 5/6 (1:50, clone D5/16 B4; Dako) and
EGFR (EGFR pharmDx™; Dako).
ER and PR were regarded positive if there were at least
1% positive tumor nuclei, according to the American
Society of Clinical Oncology/College of American Patholo-
gists guidelines [33]. Expression of HER2 and EGFR was
scored as follows: 0, no staining; 1+, weak and incomplete
membranous staining in ≥ 10% of the tumor cells; 2+,
weak to moderate, complete membranous staining in ≥
10% of the tumor cells; and 3+, strong, complete membra-
nous staining in ≥ 30% of the tumor cells. Any positive
staining was regarded as positive for EGFR, and 3+ was
considered positive for HER2. For cytokeratin 5/6, cases
with any positive membranous staining were grouped as
positive. For p53, cases with 10% or more positive staining
were grouped as positive. For the Ki-67 proliferation
index, cases with 20% or more positive tumor cells were
regarded as having high indices.
Definition of breast tumor subtypes
Breast cancer subtypes were defined according to
Voduc and colleagues [34] with minor modifications,
and were categorized as follows: luminal A (ER-positive
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or PR-positive, HER2-negative, Ki-67 < 14%), luminal B
(ER-positive or PR-positive, HER2-negative, Ki-67 ≥
14%; or ER-positive or PR-positive, HER2-positive),
HER2-positive (ER-negative, PR-negative, HER2-posi-
tive), basal-like (ER-negative, PR-negative, HER2-nega-
tive, cytokeratin 5/6-positive and/or EGFR-positive)
and triple-negative, nonbasal (negative for all markers).
HER2 positivity was determined from the FISH results.
Statistical analysis
After omitting all cases in which FISH analysis failed for
all the genes (11 cases of invasive carcinoma, 13 cases of
DCIS associated with invasive carcinoma and four cases of
pure DCIS), a total of 427 invasive carcinomas, 203 DCIS
associated with invasive carcinomas and 175 pure DCIS
were informative for at least one gene. FISH failures were
due to loss of tissue on the TMA, lack of tumor cells in
the arrayed tissue or inadequate hybridization. Statistical
significance was analyzed using Statistical Package SPSS
version 15.0 for Windows (SPSS Inc., Chicago, IL, USA).
The chi-square test or Fisher’s exact test was used
when comparing gene amplification frequencies between
groups and analyzing associations of gene amplification
with clinicopathologic characteristics of tumors. The
Spearman correlation test was used to analyze the asso-
ciation of co-amplification. For the 203 invasive carcino-
mas with DCIS components, McNemar tests were used
to see whether the (paired) differences between gene
amplification in the invasive and DCIS components of
the same tumors were significantly different. Survival
curves were estimated using the Kaplan-Meier product-
limit method, and the significance of differences between
survival curves was determined using the log-rank test.
Covariates that were statistically significant in the uni-
variate analysis were then included in the multivariate
analysis using a Cox proportional hazards regression
model; the hazard ratio (HR) and its 95% confidence
interval (CI) were assessed for each factor. P < 0.05 was
considered statistically significant. All P values reported
were two-sided.
Results
Gene amplification in pure DCIS, DCIS associated with
invasive carcinomas, and invasive carcinomas
We measured the HER2, C-MYC, CCND1 and FGFR1
amplification status in pure DCIS, DCIS associated with
invasive carcinomas, and invasive carcinomas (Figure 1).
The frequency of FGFR1 amplification was higher in
invasive carcinomas than in pure DCIS (12.5% vs. 6.0%, P
= 0.020) (Table 2 and Figure 2). On the contrary, HER2
gene amplification was more frequent in pure DCIS than
in invasive carcinomas (30.9% vs. 19.9%, P = 0.004).
C-MYC and CCND1 amplification did not differ between
the two groups. Similarly there was no significant
difference in the amplification frequencies of HER2, C-
MYC, CCND1 and FGFR1 in pure DCIS and DCIS asso-
ciated with invasive carcinomas (Table 2 and Figure 2).
In the next step, we compared gene amplification fre-
quencies in DCIS and invasive carcinomas according to
the grade of carcinoma (Table 2 and Figure 2), because
DCIS are thought to be precursors of invasive cancers of
similar grade. We found that HER2 and C-MYC amplifi-
cation frequencies differed depending on the grade of
carcinoma. In high-grade tumors, HER2 gene amplifica-
tion frequency was also significantly higher in pure DICS
than in invasive carcinoma (59.7% vs. 34.4%, P < 0.001).
Conversely, the FGFR1 amplification frequency tended to
be higher in invasive carcinoma than in pure DCIS
(15.6% vs. 6.8%, P = 0.056). HER2 amplification was more
frequent in high-grade pure DCIS than in DCIS asso-
ciated with invasive carcinoma (59.7% vs. 38.2%, P =
0.004). For low/intermediate-grade tumors, however,
there were no significant differences between the fre-
quencies of gene amplification in pure DCIS, DCIS asso-
ciated with invasive carcinomas, and invasive carcinomas.
We also evaluated co-amplification of genes and their
associations in pure DCIS and invasive carcinoma (see
Table S1 in Additional file 1). CCND1 amplification was
correlated with HER2 and FGFR1 amplification in inva-
sive carcinoma, but not in the pure DCIS.
Comparison of gene amplification in the invasive and
DCIS components of the same tumors
To evaluate the role of gene amplification in the progres-
sion of DCIS to invasive carcinomas, we compared the
gene amplification status of matched invasive and DCIS
components in the 203 cases of invasive carcinomas with
a DCIS component (Figure 3). The HER2, C-MYC,
CCND1 and FGFR1 amplification status in the invasive
and DCIS components agreed in most cases in the initial
TMA examination. For the discrepant cases, we reana-
lyzed the gene amplification status of both components
using all possible tumor sections with a DCIS component
to find the potential area of gene amplification, and found
that two of the discrepant cases in which only the invasive
component showed gene amplification in initial TMA had
a minor DCIS component with gene amplification in the
whole section (Table S2 in Additional file 2).
The combined data for initial TMA and the whole-sec-
tion examination revealed the concordance rate of 99.0%
for HER2, 96.0% for C-MYC, 98.0% for CCCND1 and
96.9% for FGFR1 amplification (Figure 3). HER2 was
amplified in both the invasive and DCIS components in
46 cases (22.8%), and in two cases (1.0%) there was
amplification only in the DCIS component. C-MYC was
amplified in 18 cases (8.9%) in both components, of
which one case showed heterogeneous amplification in
the DCIS component; that is, amplification was seen in
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some DCIS ducts but not in others. C-MYC amplification
was present only in the invasive component in six cases
(3.0%), in four of which amplification was variable. In
two cases (1.0%), only the DCIS component showed het-
erogeneous C-MYC amplification. CCND1 was amplified
in both components in 32 (15.9%) cases, in four of which
amplification in the DCIS component was heterogeneous.
CCND1 was amplified in only the DCIS component in
three cases (1.5%) and in only the invasive component in
one case (0.5%). Interestingly, amplification was hetero-
geneous in all four discordant cases. FGFR1 amplification
was observed in both components in 20 cases (10.3%), in
three of which amplification in the DCIS component was
variable. In six cases (3.1%) only the invasive component
showed FGFR1 amplification. FGFR1 amplification was
thus found to be more frequent in the invasive compo-
nent than in the DCIS component (P = 0.031).
Association of gene amplification with the
clinicopathologic characteristics of tumor
We also explored the associations between gene amplifi-
cation and the clinicopathologic variables of the tumors
Figure 1 Analysis of HER2, C-MYC, CCND1 and FGFR1 amplification by fluorescence in situ hybridization. (A) Representative examples of
HER2, C-MYC, CCND1 and FGFR1 amplification in pure ductal carcinoma in situ (DCIS). (B) Comparison of gene amplification status in the invasive
and DCIS component of the same tumors. CCND1 is amplified in both the invasive and DCIS components of a tumor. However, FGFR1 is
amplified in the invasive component but not in the DCIS component of a tumor. HER2, C-MYC, CCND1 and FGFR1-specific probes are red, and
centromeric probes (chromosome 17 for HER2, chromosome 8 for C-MYC and FGFR1, and chromosome 11 for CCND1) are green. Scale bar:
25 μm. Magnification: ×400 (H & E) and ×1,000 (fluorescence in situ hybridization).
Jang et al. Breast Cancer Research 2012, 14:R115
http://breast-cancer-research.com/content/14/4/R115
Page 5 of 12
(Table S3 in Additional file 3). In the invasive carcino-
mas, HER2 and C-MYC amplification were associated
with the aggressive features of tumor, such as high his-
tologic grade, ER/PR negativity, p53 overexpression and
high Ki-67 proliferation index. CCND1 amplification
was only correlated with ER positivity, and FGFR1
amplification was not associated with any clinicopathol-
gic features of the tumors. However, the association of
FGFR1 amplification with high histologic grade was
close to significance (P = 0.095). In pure DCIS, HER2
Table 2 Gene amplification frequencies in invasive carcinoma, DCIS associated with invasive carcinoma, and pure DCIS
Group Gene Pure DCIS DCIS associated with invasive carcinoma Invasive carcinoma P valuea P valueb
Total HER2 54/175 (30.9) 48/202 (23.8) 85/427 (19.9) 0.004 0.122
C-MYC 17/173 (9.8) 20/203 (9.9) 54/427 (12.6) 0.333 0.993
CCND1 22/175 (12.6) 35/201 (17.4) 61/424 (14.4) 0.559 0.192
FGFR1 10/168 (6.0) 21/196 (10.7) 52/417 (12.5) 0.020 0.105
High grade HER2 46/77 (59.7) 39/102 (38.2) 63/183 (34.4) < 0.001 0.004
C-MYC 12/76 (15.8) 15/103 (14.6) 42/183 (23.0) 0.196 0.821
CCND1 13/77 (16.9) 23/102 (22.5) 30/182 (16.5) 0.937 0.349
FGFR1 5/74 (6.8) 14/97 (14.4) 28/179 (15.6) 0.056 0.114
Low/intermediate grade HER2 8/98 (8.2) 9/100 (9.0) 22/230 (9.6) 0.687 0.834
C-MYC 5/97 (5.2) 5/100 (5.0) 11/230 (4.8) 1.000 1.000
CCND1 9/98 (9.2) 12/99 (12.1) 29/228 (12.7) 0.362 0.504
FGFR1 5/94 (5.3) 7/99 (7.1) 23/225 (10.2) 0.158 0.614
Data presented as n (%). P values calculated using the chi-square test or Fisher’s exact test. DCIS, ductal carcinoma in situ. aPure DCIS versus invasive carcinoma;
bPure DCIS versus DCIS associated with invasive carcinoma.
Figure 2 Frequencies of HER2, C-MYC, CCND1 and FGFR1 amplification. Frequencies of HER2, C-MYC, CCND1 and FGFR1 amplification in pure
ductal carcinoma in situ (DCIS), DCIS associated with invasive carcinoma, and invasive carcinoma. (A) HER2 gene amplification is more frequent in
pure DCIS than in invasive carcinomas in both total tumors and in high-grade tumors. (B), (C) C-MYC and CCND1 amplification rates do not
differ significantly between groups. (D) The amplification rate of FGFR1 is higher in invasive carcinomas than in pure DCIS in both total tumors
and high-grade tumors.
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and C-MYC amplification were also associated with high
nuclear grade and high Ki-67 proliferation index. How-
ever, no clinicopathologic variables of DCIS were asso-
ciated with FGFR1 amplification.
Gene amplification frequencies were also associated
with the tumor subtype (Table 3). Specifically, CCND1
amplification was not found in any of the progression
stages of basal-like breast cancer. In invasive carcinoma,
C-MYC amplification was most common in basal-like
subtype and was more frequent in the luminal B subtype
than in the luminal A subtype. CCND1 and FGFR1
amplification was most common in the luminal B sub-
type, being significantly higher than in the luminal A,
HER2-positive and triple-negative, nonbasal subtypes. In
pure DCIS, CCND1 and FGFR1 amplification was also
most common in the luminal B subtype and tended to
be more frequent in the luminal B subtype than in the
luminal A subtype (P = 0.099 and P = 0.071, respec-
tively). However, there were no significant differences in
gene amplification frequencies between pure DCIS and
invasive carcinoma within the individual subtypes,
although FGFR1 amplification frequencies were higher
(although not significantly so) in the invasive carcinomas
than in the pure DCIS in all subtypes except the triple-
negative, nonbasal subtype.
FGFR1 amplification as an independent prognostic factor
for breast cancer progression
We also investigated the prognostic role of gene amplifi-
cation in invasive breast cancer. Most patients were trea-
ted by the standard practice guidelines and have been
followed regularly after surgery. Among the 85 patients
with HER2-amplified breast cancer, 20 patients (24%)
received adjuvant trastuzumab therapy. There were five
patients with initial metastases at the time of operation,
and 422 patients were analyzed for disease-free survival.
The median follow-up time was 5 years (range 1 to 8
years). There were 10 (2.4%) loco-regional recurrences
and 34 (8.1%) distant metastases as first events. In
Kaplan-Meier survival analyses, the patients with FGFR1-
amplified breast cancer had shorter disease-free survival
times than those without it (P = 0.003; Figure 4A). On
the contrary, there were no survival differences associated
with HER-2, C-MYC or CCND1 amplification (P = 0.160,
P = 0.268, and P = 0.670, respectively). Subgroup analyses
also revealed a difference in survival between the patients
Figure 3 Gene amplification status in invasive and ductal carcinoma in situ components of the same tumors. (A) HER2, (B) C-MYC, (C)
CCND1 and(D) FGFR1 amplification status in the invasive and ductal carcinoma in situ (DCIS) components agree in most cases. Discordant cases
are found in 1.0% for HER2, 4.0% for C-MYC, 2.0% for CCND1 and 3.1% for FGFR1 in combined tissue microarray and whole-section examination.
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with and without FGFR1-amplified breast cancer in the
hormone receptor-positive group (P = 0.001; Figure 4B),
but not in the hormone receptor-negative group (P =
0.284; Figure 4C). Similarly, there was no survival differ-
ences with regard to FGFR1 amplification in the HER2-
positive subtype (P = 0.514) and the basal-like subtype
(P = 0.505).
In addition to FGFR1 amplification, high T stage (T1 to
T2 vs. T3 to T4, P < 0.001), nodal metastasis (N0 vs. N1
to N3, P = 0.002), hormone receptor negativity (P =
0.004), p53 overexpression (P = 0.005) and high Ki-67 pro-
liferation index (P = 0.006) were significantly associated
with poor disease-free survival in all patients with invasive
carcinoma. In multivariate analysis, only the T stage (pT1
to pT2 vs. pT3 to pT4, HR = 2.916, 95% CI = 1.254 to
6.781, P = 0.013), N stage (N0 vs. N1 to N3, HR = 2.585,
95% CI = 1.324 to 5.049, P = 0.005) and FGFR1 amplifica-
tion (HR = 2.794, 95% CI = 1.375 to 5.678, P = 0.001)
remained independent prognostic factors for disease-free
survival. In the hormone receptor-positive group, the N
stage (N0 vs. N1 to N3, HR = 4.514, 95% CI = 1.506 to
13.531, P = 0.007), p53 overexpression (HR = 2.757, 95%
CI = 1.029 to 7.388, P = 0.044) and FGFR1 amplification
(HR = 2.659, 95% CI = 1.042 to 6.785, P = 0.041) were
identified as independent prognostic factors.
Discussion
In this study we have shown that FGFR1 amplification is
more frequent in invasive carcinoma than in pure DCIS,
and in the invasive components of tumors with invasive
and DICS components. In addition, FGFR1 amplification
was found to be associated with decreased disease-free
survival, suggesting a role for FGFR1 amplification in the
progression of breast cancer including the in situ to inva-
sive transition.
FGFR1 was suggested to be the target oncogene impli-
cated in 8p11-12 amplification [15,35,36]. However,
Gelsi-Boyer and colleagues reported that the 8p11-12
amplicon is much more complex, and is composed of at
least four amplicons including 14 candidate oncogenes
Table 3 Relationships between gene amplification and molecular subtypes
Subtype
Histologic stage Gene Luminal A Luminal B HER2-positive Basal-like TNNB P valuea
Invasive carcinoma C-MYC 13/208 (6.3)*,** 15/103 (14.6)** 7/42 (16.7) 14/55 (25.5)* 5/19 (26.3) < 0.001
CCND1 19/205 (9.3)† 37/103 (35.9)†,‡,§ 4/42 (9.5)‡ 0/55 (0)† 1/18 (5.3)§ < 0.001
FGFR1 21/202 (10.4)¶ 21/100 (21.0)¶,††,‡‡ 3/42 (7.1)†† 7/55 (12.7) 0/18 (0)‡‡ 0.025
Pure DCIS C-MYC 6/98 (6.1) 4/24 (16.7) 6/34 (17.6) 1/9 (11.1) 0/8 (0) 0.198
CCND1 11/99 (11.1) 6/24 (25.0) 4/35 (11.4) 0/9 (0) 1/8 (12.5) 0.298
FGFR1 5/95 (5.3) 4/23 (17.4) 1/33 (3.0) 0/9 (0) 0/8 (0) 0.134
Data presented as n (%). P values calculated using the chi-square test or Fisher’s exact test. DCIS, ductal carcinoma in situ; TNNB, triple negative, nonbasal.
aBetween molecular subtypes. *P < 0.001, basal-like vs. luminal A. **P = 0.016, luminal B vs. luminal A for C-MYC. †P < 0.001, luminal B vs. luminal A, luminal B vs.
basal-like. ‡P = 0.001, luminal B vs. HER2-positive. §P = 0.008, luminal B vs. TNNB for CCND1. ¶P = 0.012, luminal B vs. luminal A. ††P = 0.044, luminal B vs. HER2-
positive. ‡‡P = 0.040, luminal B vs. TNNB for FGFR1.
Figure 4 Disease-free survival according to FGFR1 amplification status. (A) Patients with FGFR1 amplified invasive breast cancer have
significantly poorer disease-free survival than other patients. This finding applies to the hormone receptor (HR)-positive group (B) but not to the
HR-negative group (C).
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that can be amplified independently [37]. Not only
FGFR1 but also other oncogenes in the 8p11-12 ampli-
con, such as LSM1, BAG4 and C8orf4, are therefore now
accepted as contributing to oncogenesis [38,39].
Although FGFR1 is not widely accepted as the driver
breast cancer oncogene affected in the 8p11-12 amplifi-
cation, its amplification has been reported to be asso-
ciated with poor prognosis, especially in patients with
ER-positive tumors [14]. In this study, we confirmed the
prognostic impact of FGFR1 amplification, especially in
the hormone receptor-positive group. Furthermore, we
showed that FGFR1 amplification is most frequently
found in the luminal B subtype among the various breast
cancer subtypes. No correlations were found between
FGFR1 amplification and clinicopathologic features of
the tumors. In the hormone receptor-positive group,
however, FGFR1 amplification was associated with high
histologic grade (P = 0.018), PR negativity (P = 0.017)
and high Ki-67 proliferation index (P = 0.020) (data not
shown). Recently, in accord with our findings, Turner
and colleagues reported that FGFR1 signaling suppressed
PR expression and that FGFR1-amplified cancers had
higher Ki-67 proliferation indices and were most often
found in the luminal B subtype, accounting for 16 to 27%
of their series [17]. They also demonstrated that FGFR1
amplification increased resistance to endocrine therapy.
Taken together, these findings suggest that FGFR1 ampli-
fication makes an important contribution to the aggres-
sive phenotype of hormone receptor-positive breast
cancer.
Although FGFR1 amplification has been shown to be
associated with breast cancer progression, there have
been no studies of its association with the in situ to inva-
sive transition. In our study, FGFR1 amplification was
more frequent in invasive carcinoma than in pure DCIS,
and tended to be higher in invasive carcinomas than in
pure DCIS in the high-grade tumors. More importantly,
FGFR1 amplification was more frequent in the invasive
components of tumors than in the corresponding DCIS
components. The mechanism by which FGFR1 amplifica-
tion induces invasion of DCIS is unknown. However, in
the mouse mammary tumor virus-inducible FGFR1
transgenic mouse model, sustained activation of FGFR1
in the mouse mammary epithelium induces alveolar
hyperplasia and invasive lesions, which are associated
with extracellular matrix remodeling and vascular
branching in the stroma adjacent to these lesions [40].
The same authors have developed an in vitro three-
dimensional HC11 mouse mammary epithelial cell cul-
ture model expressing a drug-inducible FGFR1 and have
demonstrated that inducible FGFR1 activation results in
a gain of invasive properties and promotes the epithelial-
mesenchymal transition, which is caused by induction of
matrix metalloproteinase-3 [41]. FGFR1 amplification,
and hence increased FGFR1 signaling, therefore seems to
contribute to early breast cancer invasion; that is, the in
situ to invasive transition. This result may have clinical
implications, because DCIS with FGFR1 amplification is
more likely to progress to invasive carcinoma. In this
study, we focused on the role of genetic alterations in the
progression of DCIS to invasive carcinoma. However, a
growing body of evidence suggests that the transition of
DCIS to invasive carcinoma is strongly dependent on the
tumor microenvironment, particularly on the myoepithe-
lial cells and cancer-associated fibroblasts [42,43].
Further studies will therefore be needed to elucidate the
effect of FGFR1 amplification in epithelial cells on
the tumor microenvironment and epithelial-stromal
interactions.
We found no differences in the amplification frequen-
cies of C-MYC and CCND1 between DCIS, DCIS asso-
ciated with invasive carcinoma, and invasive carcinoma.
Burkhardt and colleagues recently examined the amplifi-
cation frequencies of HER2, ESR1, CCND1 and MYC in a
large series of pure DCIS and DCIS associated with inva-
sive carcinomas, and also found no significant differences
between them [28]. However, we obtained different
results for HER2 gene amplification. This amplification
was significantly more frequent in pure DCIS than in
invasive carcinomas, especially in high-grade tumors, and
other workers have obtained the same result [44,45].
Amplification of HER2, C-MYC and CCND1 therefore
seems to play a role in the early development of breast
cancer, but not in the progression of DCIS to invasive
carcinomas.
In a comparison of the matched DCIS and invasive com-
ponents of the same tumors we demonstrated that the
genetic changes in the two components were similar in
terms of HER2, C-MYC and CCND1 gene amplification.
However, we detected amplification in the DCIS compo-
nents but not in the invasive carcinoma components in a
few cases for HER2 (n = 2), C-MYC (n = 2) and CCND1
(n = 3). Interestingly, the two cases with C-MYC amplifica-
tion and the three cases with CCND1 amplification in only
the DCIS component showed heterogeneous amplifica-
tion. Four of the 32 cases with CCND1 amplification in
both components and three of the 20 cases that had
FGFR1 amplification in both components also had hetero-
geneous amplification in the DCIS component. Further-
more, in pure DCIS, heterogeneity of gene amplification
was found in 3.7% (2/52) for HER2, 11.8% (2/17) for C-
MYC, 22.7% (5/22) for CCND1 and 10% (1/10) for FGFR1
amplified cases (data not shown). These findings suggest
that intra-tumoral genetic heterogeneity is already present
in the DCIS and that progression of DCIS to invasive car-
cinomas may result from selection of subpopulations of
tumor cells. In a previous study we reported that the dif-
ferences in molecular subtypes among the invasive tumor
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foci of multifocal/multicentric breast cancers were asso-
ciated with mixed molecular subtypes in the DCIS compo-
nents, suggesting that heterogeneity within the DCIS
followed by selection of different clones might give rise to
the different phenotypes in multicentric/multifocal breast
cancers [46]. Supporting this concept, Hernandez and col-
leagues recently performed comparative analyses of
known cancer genes using microarray-based comparative
genomic hybridization and Sequenom MassARRAY
(OncoCarta Panel v 1.0, Sequenom, San Diego, CA, USA)
in matched DCIS and adjacent invasive carcinomas, and
suggested that although the modal populations of both
components were similar at the genetic level, the progres-
sion from DCIS to invasive ductal carcinoma was driven
in some cases by selection of nonmodal clones with speci-
fic genetic aberrations [47].
The different breast cancer subtypes have been sug-
gested to have distinct patterns of copy number altera-
tions. While higher numbers of gains/losses have been
associated with the basal-like subtype, high-level DNA
amplification has been found in the luminal B and HER2-
positive subtypes [48], and candidate oncogenes have been
identified in chromosomal regions 1q21-23, 10p14 and
12p13 for basal-like breast cancers, but in regions 1q21-
23, 8p12-q21, 11q13 and 16p12-13 for luminal breast can-
cers [4]. Moreover, CCND1 amplification on 11q13 has
been reported to be associated with luminal subtypes [16],
and in agreement with this we found that CCND1 and
FGFR1 amplification was most frequent in the luminal B
subtype whereas CCND1 amplification was absent from all
of the basal-like breast cancers.
Conclusion
In summary, we have studied the amplification frequen-
cies of HER2, C-MYC, CCND1 and FGFR1 in a large
series of pure DCIS, DCIS associated with invasive carci-
noma, and invasive carcinomas, to investigate the role of
gene amplification in the progression of DCIS to inva-
sive carcinoma. The amplification frequencies of C-MYC
and CCND1 did not differ between pure DCIS and inva-
sive carcinomas, and HER2 amplification was more fre-
quent in pure DCIS. The HER2, C-MYC, CCND1 and
FGFR1 amplification status was in most cases concor-
dant in the matched invasive and DCIS components of
the same tumors, pointing to early roles in the develop-
ment of breast cancer. However, FGFR1 amplification
was more frequent in invasive carcinomas than in pure
DCIS, and in the invasive components of the same
tumors. Furthermore, FGFR1 amplification was found to
be an independent prognostic factor for disease-free sur-
vival. Our results therefore suggest that FGFR1 amplifi-
cation play an important role in the progression of
breast cancer, including the in situ to invasive transition,
as well as initiation.
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characteristics in invasive (A) and in situ (B) breast carcinomas.
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